Latest News
Corcept Therapeutics Incorporated
- Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ)
- U.S. Markets Declined Friday; Corcept Therapeutics Fell Furthest
- Why is Corcept Therapeutics stock tumbling today?
- The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
- Corcept Therapeutics director Wilson sells $1.15 million in shares
- Form 4 Corcept Therapeutics Incorporated: James N. Wilson (Director) For: 15 October
- Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)
- Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth
- Corcept Therapeutics chief accounting officer sells $1.16m
- Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027
- Corcept Therapeutics’ oncology president sells $29,842 in stock By Investing.com
- Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →